FOXC1 and acute myeloid leukemia: While further studies are needed in this regard, patients diagnosed with FOXC1+ AML should probably be recommended to enroll in clinical trials examining the efficacy of combination therapy protocols that combine various targeted therapies with standard induction chemotherapy.